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Background: Epidemiological data on statins and breast cancer risk have been inconclusive. The aim of this study
was to clarify the role of statins in breast cancer risk by studying their effect on mammographic density.
Methods: The KARolinska MAmmography project for risk prediction of breast cancer (KARMA) includes 70,877 women
who underwent either a screening or clinical mammography from January 2011 to December 2013. In total, 41,102
women responded to a web-based questionnaire, and had raw digital mammograms stored. Volumetric
mammographic density was measured using Volpara™ and information on statin use was obtained through
linkage with the Swedish National Prescription Register. Analysis of covariance was used to study the effect of
statin use on mammographic density, adjusting for a large set of potential confounders. We also studied the effects of
statin class and treatment duration and tested for potential effect modification by hormone replacement therapy (HRT).
Results: Statin use was recorded in 3,337 women (8.1 %) of the study population and lipophilic statins was the most
commonly prescribed type (93.4 % of all statin users). After multivariable adjustment, percent dense volume was lower
in statin users than in non-users (P < 0.001). This association was explained by a larger absolute non-dense volume in
statin users (P < 0.001). Overall, no difference in absolute dense volume was detected, but interaction analyses revealed
a larger dense volume among statin users who reported ever HRT use (P = 0.03). No differential effects were observed
according to statin lipophilicity and treatment duration.
Conclusions: We observed no overall effect of statin use on mammographic density in terms of absolute dense
volume, although a larger absolute dense volume was observed in statin users who reported ever HRT use, which
requires further investigation.
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Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl co-
enzyme A (HMG-CoA) reductase and are used world-
wide as an efficient cholesterol-lowering medication with
proven anti-inflammatory properties [1]. By reducing
HMG-CoA reductase activity, levels of mevalonate de-
crease, which influences important down-stream players
for cellular pathways that are crucial for cancer initiation,
growth, and metastasis [2]. Pre-clinical studies and phase
II trials have demonstrated anti-carcinogenic properties of
statins [3–5]. Large-scale epidemiological observational
studies have reported conflicting findings regarding the* Correspondence: signe.borgquist@med.lu.se
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unless otherwise stated.role of statins in breast cancer prevention [6–11]. On the
other hand, available data on breast cancer prognosis are
more consistent showing a lower risk of recurrence in
lipophilic statin users [12–14]. These data suggest that sta-
tins may not prevent cancer occurrence, e.g. by affecting
the malignant genotype, but rather inhibit the progress of
an existing cancer by affecting the malignant phenotype
[11]. Mammographic density (MD), which reflects the
amount of fibroglandular or radio dense tissue on an
X-ray of the breast (mammogram), is a strong determin-
ant of breast cancer risk [15, 16]. Women with extremely
dense breasts (>75 % dense tissue on a mammogram) have
a 4–6 fold higher risk of developing breast cancer com-
pared to women having fatty or non-dense breasts (<5 %
dense tissue) [15]. MD also shares many risk factors with
breast cancer and is therefore seen as an intermediate inal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MD have also been proven to cause cancer [18] and MD
may be a useful marker in studies aiming at elucidating
the role of potential risk factors for breast cancer [19, 20].
To clarify the effect of statins on breast cancer risk, we de-
cided to study the association between statin use and
volumetric mammographic density in a large-screening
based cohort with comprehensive information on medica-
tion use, lifestyle factors and volumetric mammographic
density.Methods
Study population
The KARolinska MAmmography project for the risk pre-
diction of breast cancer (KARMA) is a prospective cohort
study initiated in January 2011 and comprises 70,877
women who attended mammography screening or clinical
mammography at four hospitals in Sweden [21]. Partici-
pants responded to a detailed web-based questionnaire,
and permission was asked for storage of “for processing”
(raw) full-field digital mammograms (FFDM) and linkage
to Swedish national registers on inpatient care, prescrip-
tions, cancer, and cause of death.
For the present study, we selected all women who
attended the mammography screening program (40–74
years) with raw digital mammograms stored at baseline
(N = 50,461). We excluded women with previous can-
cers other than non-melanoma skin cancer (N = 3,015),
women who underwent breast enlargements/reductions/
surgery (N = 2,191), women lacking information on age
and body mass index (BMI) (N = 3,908), and women preg-
nant 12 months prior to study entry (N = 40), leaving
41,307 women in the study. Of these, 41,102 women had
medio-lateral oblique (MLO) mammograms and repre-
sented the final study population. The study was approved
by the ethical review committee at the Karolinska Institute
(Stockholm, Sweden), and all participants provided writ-
ten informed consent.Statin exposure
Information on statin use was obtained through linkage
to the Swedish Prescribed Drug Register [22], which has
had nationwide coverage since mid-2005. The register
covers all drugs sold and dispensed by prescription at
Swedish pharmacies to patients with a personal identifica-
tion number. The following Anatomical Therapeutic Chem-
ical (ATC) codes were extracted: ‘C10AA01’ (simvastatin),
‘C10AA04’ (fluvastatin), ‘C10AA05’ (atorvastatin) and
‘C10AA08’ for lipophilic statins, and ‘C10AA03’ (prava-
statin) and ‘C10AA07’ (rosuvastain) for hydrophilic statins.
Women were considered to be current users if they were
dispensed statins during the year before mammography.
We also calculated and categorized the cumulative statinduration in current users in three-year categories (<2 years,
2–5 years, >5 years).
Measurement of mammographic density
Mammographic density was measured from baseline mam-
mograms using a fully automated volumetric method,
Volpara, which has been validated against breast magnetic
resonance imaging (MRI) data and appears to be robust to
changes in imaging conditions [23]. We have previously
shown that Volpara performs well in a high-throughput
setting with both percent and absolute dense volumes be-
ing associated with established density determinants and
breast cancer risk [24]. For our analyses, we used the aver-
age mammographic density from the left and right breast
of the MLO view.
Technical details of the Volpara algorithm have been
described elsewhere [23]. In brief, the algorithm computes
the thickness of dense tissue at each pixel using the X-ray
attenuation of an entirely fatty region as an internal refer-
ence. The absolute dense volume (cm3) is measured by in-
tegrating the dense thickness at each pixel over the whole
mammogram, and the total breast volume (cm3) is derived
by multiplying the breast area by the recorded breast
thickness with an appropriate correction for the breast
edge. The percent dense volume (%) is obtained from the
ratio of these two measures, and the absolute non-dense
volume is derived by subtracting the absolute dense vol-
ume from the total breast volume.
Covariate assessment
Information on potential confounders was derived from
the web-based questionnaire. The questionnaire covers a
wide range of breast cancer risk factors and other base-
line characteristics such as anthropometrics, alcohol and
smoking, education, reproductive and hormonal factors
(age at menarche, number of births and age at first birth,
menstruation status, use of oral contraceptives and hor-
mone replacement therapy (HRT)), and family history of
breast cancer. Body mass index (BMI) was calculated based
on self-reported weight and height. Menopausal status was
defined according to information on menstruation status,
previous oophorectomy, and age at study entry. Women
with no periods during the last year, a history of oophorec-
tomy, or age 55 or older were defined as postmenopausal.
Information on other medications was extracted from the
Swedish Prescribed Drug Register using the following
ATC codes: ‘B01AC06’ (low-dose aspirin) and ‘A10BA02’
(metformin). Current use was defined by dispensing within
the year preceding mammography.
Statistical methods
Characteristics of statin users were compared with those
of non-users using Chi-square tests for categorical variables
and T-tests for continuous variables. All mammographic
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distribution. We used analysis of covariance (ANCOVA)
to examine associations between statin use and mammo-
graphic density, and geometric means were calculated for
each category of statin use. We also studied the effect
of statin class (lipophilic vs. hydrophilic) and treatment
duration. Women using both lipophilic and hydrophilic
statins were included in analyses of overall statin use
and treatment duration but were excluded from analysis
by statin class (N = 46).
All analyses were adjusted for potential confounders
in a stepwise manner. We started with an age-adjusted
model, after which BMI was added. In the third model,
we further adjusted the analyses for other known deter-
minants of mammographic density confounders, in-
cluding menopausal status, HRT use, parity/age at first
birth, age at menarche, education level, smoking, alco-
hol consumption, and history of benign breast disease.
In the final multivariable adjusted model, we added co-
medication including low-dose aspirin and metformin
use.
Since the effect of statins on breast cancer risk may
depend on HRT use [25], we also tested for potential
effect modification by HRT by adding a multiplicative
interaction term between statin and any history of HRT
use to the multivariable adjusted models. All statistical
analyses were conducted using STATA version 12.0 (Stata
Corp. College Station, TX, USA). Seventeen percent of the
women had missing values on one or more covariates.
On the basis of the missing data pattern, we assumed the
missing values to be “missing at random” [26], and im-
puted these values using a multiple imputation technique
(10 imputation sets) [27].
Results
Table 1 shows the characteristics of statin users and non-
users. Statin use was recorded in 3,337 women (8.1 %) of
the KARMA study population. As expected, statin users
were more likely to be of older age, to be postmenopausal,
and to have a higher BMI and a smoking history. Statin
users also more often reported HRT use in the past and
were more frequently on low-dose aspirin and metformin
medication. Other variables associated with statin use
were age at menarche, age at first birth, oral contracep-
tive use, and alcohol intake.
The distribution of statin use by lipophilicity, type, and
duration is summarized in Table 2. Most statin users were
prescribed a lipophilic statin (93.4 %), with simvastatin
being the most commonly prescribed type. Among current
users, the percentages of participants using statins <2 years,
2–5 years, and >5 years were 15.1 %, 38.5 % and 46.4 %
respectively.
Table 3 shows the geometric means of mammographic
density by statin use, lipophilicity, and statin duration.Overall, percent dense volume was lower in statin users
than in non-users (P < 0.001). The largest difference in
percent dense volume was observed in the age-adjusted
model, while the effect of statin use was attenuated after
adjustment for BMI, resulting in smaller difference in geo-
metric means despite being significant. Inspection of the
individual density components revealed that the inverse
association with percent dense volume was attributed
to a larger absolute non-dense volume in statin users
(P < 0.001). No effect of statin use on the absolute dense
volume was found after multivariable adjustment, although
a trend towards a higher dense volume was observed after
adjusting for concomitant use of low-dose aspirin and
metformin (P = 0.06). There was also no evidence of dif-
ferential effects by lipophilicity and treatment duration
according to overlapping confidence intervals. Both lipo-
philic and hydrophilic statin users had a lower percent
dense volume and higher absolute non-dense volume com-
pared to non-users. The differences in density measures
by statin duration was driven by the strong overall effect
of statin use, without a clear trend by length of exposure
in current users as demonstrated by the U-shaped
associations.
Interaction analyses showed evidence of effect modifi-
cation by HRT. A positive association between statin use
and the absolute dense volume was found in those who
had used HRT, while no such association was found in
never HRT users (Pinteraction = 0.03) (Table 4).
Discussion
In this study including 41,102 women from a large
screening-based cohort, we found no evidence of an over-
all effect of statin use on absolute dense volume. Statin
users had a significantly lower percent dense volume,
but this difference was mainly attributable to a larger
non-dense volume in statin users. While a large number
of studies have investigated the effect of statin use on
breast cancer risk and prognosis [6–14], only few studies
have examined the association with mammographic
density. Our results are in line with a longitudinal study
showing no effect of statins on change in area-based
mammographic density [28]. No differential effects were
observed by statin class or treatment duration [13, 29] but
interaction analyses revealed potential effect modification
by HRT with a larger absolute dense volume among statin
users who also reported HRT use.
Mammographic density can be expressed in both ab-
solute and relative terms. The preferred MD measure for
breast cancer risk prediction is debated, although recent
studies show that the proportion of dense breast tissue
may have a stronger predictive value than the absolute
amount of dense tissue, thus suggesting non-dense tissue
as a contributing risk factor [30, 31]. Percent dense volume
mirrors the relationship between dense and non-dense
Table 1 Descriptive characteristics of the study population, overall and stratified by current statin use
Participant characteristica Total Statin use P value
No Yes
N = 37,765 N = 3,337
Age (years), mean (SD) 55.0 (9.8) 54.2 (9.6) 63.8 (6.9) <0.001
Body mass index (kg/m2), mean (SD) 25.4 (4.2) 25.2 (4.2) 27.1 (4.6) <0.001
Age at menarche (years), mean (SD) 13.1 (1.5) 13.1 (1.5) 13.3 (1.5) <0.001
Parity, % (N) 0.54
0 12.1 (4,979) 12.2 (4,582) 11.9 (397)
1 14.1 (5,792) 14.0 (5,294) 15.0 (498)
2 48.5 (19,901) 48.5 (18,296) 48.2 (1,605)
> = 3 25.3 (10,363) 25.3 (9,533) 24.9 (830)
Age at first birth (years), mean (SD) 27.1 (5.2) 27.2 (5.2) 25.0 (4.6) <0.001
Menopausal status, % (N) <0.001
Premenopausal 40.2 (16,506) 43.1 (16,272) 7.0 (234)
Perimenopausal/unknown 3.3 (1,349) 3.5 (1,304) 1.4 (45)
Postmenopausal 56.6 (23,247) 53.5 (20,189) 91.6 (3,058)
Oral contraceptive use, % (N) 79.7 (32,602) 80.5 (30,257) 70.9 (2,345) <0.001
Hormone replacement therapy, % (N) <0.001
Never 80.5 (30,791) 81.7 (28,809) 65.6 (1,982)
Former 15.5 (5,945) 14.3 (5,040) 30.0 (905)
Current 4.0 (1,521) 4.0 (1,395) 4.2 (126)
Benign breast disease, % (N) 22.1 (8,919) 22.0 (8,156) 23.3 (763) 0.09
Family history of breast cancer, % (N) 13.2 (5,236) 13.2 (4,815) 13.2 (421) 0.91
Low-dose aspirin use, % (N) 4.7 (1,911) 2.2 (833) 32.3 (1,078) <0.001
Metformin use, % (N) 1.6 (666) 0.7 (263) 12.1 (403) <0.001
Education, % (N) <0.001
Compulsory 14.4 (5,705) 12.9 (4,726) 31.2 (979)
Gymnasium 31.6 (12,557) 31.9 (11,664) 28.5 (893)
University 54.0 (21,440) 55.2 (20,178) 40.3 (1,262)
Smoking status, % (N) <0.001
Never 48.2 (19,750) 48.8 (18,400) 40.6 (1,350)
Former 39.7 (16,269) 39.1 (14,726) 46.4 (1,543)
Current 12.2 (4,984) 12.1 (4,551) 13.0 (433)
Alcohol (g/week), % (N) <0.001
0 19.4 (7,912) 18.9 (7,090) 24.9 (822)
1–25 24.0 (9,788) 24.3 (9,110) 20.5 (678)
25–50 28.1 (11,471) 28.4 (10,640) 25.2 (831)
50–100 14.6 (5,949) 14.6 (5,481) 14.2 (468)
>100 13.9 (5,666) 13.8 (5,162) 15.3 (504)
aMissingness on all variables < 5 %, except for age at first birth (5.6 %) and hormone replacement therapy (6.9 %)
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dense volume is strongly influenced by the amount of
non-dense tissue in the breast, any factor that is associ-
ated with a difference in non-dense volume can lead to
a substantial difference in percent dense volume, even if
there is no association with the absolute dense volume.Since most statin users have a medical history of hyper-
cholesterolemia and are more likely to have larger fat de-
posits than non-users, their lower percent dense volume,
as observed in this study, is most likely due to the under-
lying indication, as reflected by their larger absolute non-
dense volume. We therefore believe that the absolute
Table 2 Details of statin use in current users (N = 3,337)
% (N)














<2 years 15.1 (503)
2–5 years 38.5 (1,286)
>5 years 46.4 (1,548)
aExclusive use only. Lipophilic statins: simvastatin, atorvastatin, fluvastatin,
pitavastatin; Hydrophilic statins: rosuvastatin, pravastatin
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effect of statins on mammographic density, as this meas-
ure is less influenced by this type of confounding [32].
The role of statins in primary breast cancer prevention
is controversial, and several factors need to be acknowl-
edged when interpreting the available evidence. First of
all, our study highlights the issue of confounding by in-
dication, an effect that cannot easily be controlled for in
observational studies [33]. Any protective effect of sta-
tins may be counteracted in observational analyses due
to the underlying indication of dyslipidemia, as high total
cholesterol and low HDL cholesterol levels have been
associated with an increase in breast cancer risk in post-
menopausal women [34, 35], although a recent publication
report opposite findings with positive associations between
HDL and breast cancer risk [36]. The notion that statin
use and body composition are strongly interrelated, an-
other effect not easily adjusted for in association ana-
lyses, may also partly explain the conflicting observational
data regarding the effect of statins on breast cancer
risk [6–8, 13].
Another shortcoming in many studies may be the lack
of separate analyses for lipophilic and hydrophilic statins
[7]. Theoretically, lipophilic statins, in contrast to hydro-
philic statins, are able to penetrate the cell membrane and
affect cell proliferation and survival, hence having anti-
carcinogenic effects [37]. Regarding uptake in the hepato-
cyte cell, lipophilic statins are passively diffused throughmembranes, whereas hydrophilic statins have an active
carrier-mediated uptake [38]. The different mechanisms
of uptake generate less hepato-selectivity in lipophilic sta-
tins [38]. Animal studies have shown greater distribution
in extrahepatic tissue for lipophilic statins [39]. Thus, lipo-
philic statins, in comparison to hydrophilic statins, have
superior influence on extrahepatic tissue. However, in
this study, analyses stratified for statin lipophilicity did
not show a significant difference in absolute dense vol-
ume. Finally, bioavailability differs among statins, and the
distribution to different tissues is dose-dependent [2].
The effectiveness of statins, which were initially designed as
hepatoselective drugs [40], has been questioned as a cancer-
preventive drug considering its low systemic availability [10].
Recently, we conducted a window-of-opportunity trial, pre-
scribing a high-dose lipophilic statin (atorvastatin) to newly
diagnosed breast cancer patients two weeks prior to primary
breast cancer surgery. The study showed significantly
reduced proliferation (Ki67) in the subgroup of patients
where tumors expressed the target for statins, HMG-CoA
reductase [4]. These results imply that statins may exert
systemic effects including tumor-targeted effects in breast
cancer, despite its hepatoselective properties. Similar anti-
proliferative effect of lipophilic statins have been demon-
strated in another window trial [5]. Therefore, statins and
their role as anti-cancerous drug, requires further investi-
gation, in particular long-term use of high-dose lipophilic
statins [41].
Despite the lack of an overall association with statin
use, the higher absolute dense volume found in statin
users who also reported HRT is of interest. HRT use is
associated with an increase in MD [42] and breast can-
cer risk [43, 44], and the effect of HRT seems to depend
on the pretreatment level of endogenous estrogens. Data
from the Women’s Health Initiative trial show that the
adverse effect of HRT on breast cancer risk is largest in
those having the lowest estrogen levels [45]. Data on the
effect of statins on endogenous estrogen levels are scarce,
but a small biomarker study reported lower estrone sulfate
levels in women using simvastatin [28]. Given the larger
HRT effect in a low endogenous estrogen environment,
this may explain the larger absolute dense volume ob-
served with statins in ever HRT users. Moreover, an inter-
action between statin and HRT use has previously been
reported for breast cancer [25], in a direction similar to
that observed for the absolute dense volume. An alterna-
tive explanation for the observed interaction is the under-
lying indication. A metabolite of cholesterol has been
associated with estrogen positive breast cancers [46], sup-
porting a cross talk between estrogen and cholesterol in
breast cancer. Thus, the larger absolute dense volume in
statin users who ever used HRT could also reflect the
combined effect of HRT and underlying disease of hyper-
cholesterolemia (rather than the actual statin prescription)
Table 3 Geometric means (95 % CI) of volumetric mammographic density measures by current statin use
Geometric mean (95 % CI)a
Model 1 Model 2 Model 3 Model 4
Statin use
Percent dense volume (%) No 8.01 (7.97–8.05) 7.93 (7.90–7.96) 7.93 (7.90–7.96) 7.94 (7.91–7.97)
Yes 6.89 (6.77–7.01) 7.73 (7.63–7.84) 7.74 (7.63–7.85) 7.66 (7.54–7.77)
P value <0.001 0.001 0.001 <0.001
Absolute dense volume (cm3) No 56.8 (56.6–57.1) 57.1 (56.8–57.3) 57.1 (56.8–57.3) 57.0 (56.8–57.3)
Yes 60.7 (59.7–58.5) 57.6 (56.7–58.5) 57.5 (56.7–58.4) 58.0 (57.0–59.0)
P value <0.001 0.31 0.32 0.06
Absolute non-dense volume (cm3) No 643 (639–647) 653 (650–656) 653 (650–656) 652 (649–655)
Yes 808 (791–826) 676 (666–686) 675 (665–685) 689 (678–700)
P value <0.001 <0.001 <0.001 <0.001
Statin type
Percent dense volume (%) None 8.01 (7.98–8.05) 7.93 (7.90–7.97) 7.93 (7.90–7.97) 7.94 (7.91–7.97)
Lipophilic 6.92 (6.80–7.04) 7.73 (7.65–7.87) 7.77 (7.66–7.88) 7.69 (7.57–7.81)
Hydrophilic 6.46 (6.05–6.89) 7.32 (6.94–7.71) 7.34 (6.97–7.73) 7.26 (6.90–7.65)
P value <0.001 <0.001 <0.001 <0.001
Absolute dense volume (cm3) None 56.8 (56.6–57.1) 57.1 (56.8–57.3) 57.1 (56.8–57.3) 57.0 (56.8–57.3)
Lipophilic 60.8 (59.8–61.8) 57.7 (56.8–58.6) 57.7 (56.8–58.6) 58.1 (57.2–59.1)
Hydrophilic 58.2 (54.7–61.8) 55.0 (51.9–58.3) 54.8 (51.8–58.1) 55.3 (52.2–58.6)
P value <0.001 0.20 0.66 0.21
Absolute non-dense volume (cm3) None 643 (639–647) 653 (650–656) 653 (650–656) 652 (649–655)
Lipophilic 807 (789–825) 675 (664–685) 674 (664–685) 688 (676–699)
Hydrophilic 830 (765–900) 683 (646–723) 679 (642–718) 693 (655–733)
P value <0.001 <0.001 0.03 0.003
Statin duration
Percent dense volume (%) None 8.01 (7.97–8.05) 7.93 (7.90–7.96) 7.93 (7.90–7.96) 7.94 (7.91–7.97)
<2 years 7.00 (6.71–7.31) 7.54 (7.29–7.81) 7.64 (7.38–7.90) 7.57 (7.32–7.84)
2–5 years 6.76 (6.58–6.95) 7.59 (7.43–7.76) 7.63 (7.47–7.80) 7.56 (7.40–7.73)
>5 years 6.96 (6.79–7.14) 7.92 (7.77–8.08) 7.86 (7.71–8.02) 7.77 (7.61–7.96)
P trend <0.001 0.03 0.01 <0.001
Absolute dense volume (cm3) None 56.8 (56.6–57.1) 57.1 (56.8–57.3) 57.1 (56.8–57.3) 57.0 (56.8–57.3)
<2 years 58.5 (56.2–60.9) 56.6 (54.5–58.8) 57.0 (54.9–59.2) 57.3 (55.2–59.5)
2–5 years 60.6 (59.1–62.2) 57.5 (56.2–58.9) 57.8 (56.4–59.2) 58.2 (56.8–59.7)
>5 years 61.4 (60.0–62.9) 57.9 (56.6–59.2) 57.5 (56.2–58.8) 58.0 (56.7–59.4)
P trend <0.001 0.20 0.32 0.06
Absolute non-dense volume (cm3) None 643 (639–647) 653 (650–656) 653 (650–656) 652 (649–655)
<2 years 767 (727–809) 683 (659–709) 680 (655–705) 689 (664–715)
2–5 years 825 (798–854) 690 (674–706) 689 (673–705) 702 (685–719)
>5 years 809 (784–834) 661 (647–676) 663 (649–677) 678 (662–693)
P trend <0.001 0.001 <0.001 <0.001
aAll volumetric mammographic density measures were log transformed for analysis and the values shown are on a back-transformed scale
P value refers to F-test for between-statin group differences in geometric means, while P trend refers to linear trend analyses entering statin duration (<2 years,
2–5years, > 5 years) as continuous term in the analysis
Model 1: adjusted for age (years)
Model 2: Model 1 + body mass index (kg/m2)
Model 3: Model 2 + menopausal status (pre, peri/unknown, post), HRT use (never, former, current), parity/age at first birth (nulliparous, 1 child age at first
birth < 25 years, 1 child age at first birth ≥ 25 years, 2 children age at first birth < 25 years , 2 children age at first birth ≥ 25 years, ≥ 3 children age at first
birth < 25 years, ≥ 3 children age at first birth ≥ 25 years), age at menarche (years), education level (compulsory, gymnasium, university), smoking (never,
former, current), alcohol consumption (nondrinker, 0,1–1,9 g/day, 2.0–4.9 g/day, 5.0–9.9 g/day, ≥10 g/day) and benign breast disease (yes vs. no) +
Model 4: Model 3 plus low-dose aspirin (yes vs. no) and metformin use (yes vs. no)
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Table 4 Multivariable adjusted geometric means (95 % CI) of volumetric mammographic density measures
Geometric mean (95 % CI)a
N Statin use Percent dense volume (%) Absolute dense volume (cm3) Absolute non-dense volume (cm3)
BMI < 25 kg/m2 22,385 No 10.1 (10.0–10.1) 51.6 (51.3–52.0) 455 (452–457)
Yes 9.5 (9.3–9.7) 53.0 (51.5–54.5) 498 (485–511)
P value <0.001 0.09 <0.001
BMI 25–30 kg/m2 13,273 No 6.5 (6.5–6.6) 62.5 (62.0–62.9) 887 (882–893)
Yes 6.4 (6.2–6.5) 62.5 (61.1–64.0) 914 (895–933)
P value 0.04 0.94 0.01
BMI > 30 kg/m2 5,444 No 4.8 (4.7–4.8) 68.9 (68.1–69.6) 1362 (1350–1416)
Yes 4.8 (4.7–4.9) 69.9 (67.9–72.0) 1385 (1352–1419)
P value 0.88 0.38 0.23
Premenopausal 17,855 No 9.7 (9.7–9.8) 62.9 (62.4–63.3) 573 (569–576)
Yes 9.3 (8.8–9.7) 62.1 (58.6–65.9) 598 (567–632)
P value 0.04 0.69 0.12
Postmenopausal 23,247 No 6.8 (6.8–6.8) 52.9 (52.6–53.2) 720 (716–724)
Yes 6.5 (6.4–6.6) 53.9 (53.1–54.8) 767 (755–779)
P value <0.001 0.04 <0.001
Never HRTb 14,407 No 6.7 (6.7–6.8) 52.9 (52.5–53.2) 724 (719–729)
Yes 6.4 (6.3–6.5) 53.4 (52.3–54.5) 760 (747–774)
P value <0.001 0.38 <0.001
Ever HRTb 6,475 No 6.9 (6.8–6.9) 53.0 (52.5–53.6) 723 (718–729)
Yes 6.6 (6.5–6.8) 55.2 (53.7–56.7) 771 (755–787)
P value 0.02 0.01 <0.001
P interactionb 0.61 0.03 0.11
aAll mammographic density measures were log transformed prior to analysis and the values shown are on a back-transformed scale. bIn postmenopausal women
only. P value refers to F-test for between-statin group differences in geometric means. P interaction refers to the P value of the multiplicative interaction term
Model 4: Adjusted for age (years), body mass index (kg/m2), menopausal status (pre, peri/unknown, post), HRT use (never, former, current), parity/age at first birth
(nulliparous, 1 child age at first birth < 25 years, 1 child age at first birth ≥ 25 years, 2 children age at first birth < 25 years, 2 children age at first birth ≥ 25 years,
≥ 3 children age at first birth < 25 years, ≥ 3 children age at first birth ≥ 25 years), age at menarche (years), education level (compulsory, gymnasium, university),
smoking (never, former, current), alcohol consumption (nondrinker, 0,1–1,9 g/day, 2.0–4.9 g/day, 5.0–9.9 g/day, ≥10 g/day) and benign breast disease (yes vs. no),
low-dose aspirin use (yes vs. no) and metformin use (yes vs. no)
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represents one of the strongest risk factors for breast
cancer, potential adverse effects of statins and/or hyper-
cholesterolemia in women using HRT require further
exploration.
Our study has several strengths, including the large
screening-based cohort with detailed information on life-
style factors as well as registry-based information on statin
use and other medications. We used a fully-automated
method for measuring mammographic density, which in
contrast to other methods is not prone to subjective meas-
urement error. Moreover, volumetric approaches yield
more accurate density measures, as they account for inter-
individual differences in breast thickness. Both dense
and non-dense tissues were evaluated in this study, which
strengthens the interpretation of our findings and
highlighted the issue of confounding by indication. Ourstudy also has some limitations. The cross-sectional na-
ture limits the ability to explore the temporal association
between statins and mammographic density in terms of
initiation and discontinuation. Also, we could not study
the effect of long-term treatment (>10 years), because the
population-based prescription register has only reached
full coverage since 2005. Finally, we did not have data
available on the dosages prescribed.Conclusions
In conclusion, we found no strong evidence for an overall
effect of statin use on volumetric mammographic density
in terms of absolute dense volume. The observed inter-
action with HRT with a larger absolute dense volume in
statin users, who also reported HRT use, requires further
investigation.
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